EyePoint is on a steeply upward sloping growth path with two relatively new treatments and a third one on the way. However, the coronavirus pandemic is hobbling the growth path of one of these (DEXYCU), but the company has intervened to save cash. We think establishing an initial position at these levels is likely to […]
Entries Tagged as 'EYPT'
April 14th, 2020 · Comments Off on EyePoint Still Has A Very Promising Future
December 10th, 2019 · Comments Off on EyePoint Pharmaceuticals Faces A Big Opportunity
The company has launched two products, DEXYCU and YUTIQ. Both have very substantial market potential, and orders are ramping fast. Due to a situation with its distributor, the ramp in orders hasn’t translated into an acceleration in revenue. Quite the contrary, in fact. This disconnect between orders and revenue is clouding the assessment on how […]
August 31st, 2019 · Comments Off on EyePoint Pharmaceuticals Is Eyeing 2 Big Market Opportunities
EyePoint Pharmaceuticals has just introduced two new treatments, YUTIQ and DEXYCU, both involve the slow release of steroids to prevent eye infections. Most of the elements for successful market penetration are already in place, and these markets are substantial. Depending on the speed of growth, the company might need another financing. While speculative, it’s a […]